Table 1

 Patients’ characteristics at baseline*

Baseline variableRemission group† (n = 30)Non-remission group (n = 104)p Value‡
Anti-CCP, anti-cyclic citrullinated protein; CRP, C reactive protein; DAS, Disease Activity Score; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; HLA, human leucocyte antigen; RA, rheumatoid arthritis; RF, rheumatoid factor; SHS, Sharp–van der Heijde.
*Except where otherwise indicated, values are the mean (SD). Positive cut-off values were as follows: for IgM RF, ⩾20 IU/ml; for IgA RF, ⩾7 U/ml; for anti-CCP antibodies, ⩾50 U/ml.
†The remission group was defined by patients with RA with DAS<1.6 both at 3 and 5 years.
‡p Values for the comparison of the two groups.
§DRB1*04 includes DRB1*0401, 0404, 0405 and 0408.
¶SHS on radiographic evaluation of the hands and feet.
Women, n(%)21 (70)81 (77.9)0.37
Age at RA diagnosis, years44.3 (13.9)47.8 (11.8)0.20
Disease duration, months6.79.20.21
HAQ1.12 (0.69)1.41 (0.70)0.04
DAS3.70 (0.94)4.24 (0.72)0.002
ESR, mm/h32.6 (23.5)43.5 (29.2)0.75
CRP, mg/l19.8 (25.3)40.7 (49.7)0.02
RF positivity, n (%)
    IgM RF13 (46.4)65 (70)0.02
    IgA RF17 (60.7)71 (76.3)0.10
Anti-CCP antibody,n (%)12 (48)45 (53.6)0.62
HLA-DRB1*04,n (%) §14 (48.3)50 (49.5)0.91
HLA-DRB1*01,n (%)9 (31.0)29 (28.7)0.81
Total SHS¶4.67 (9.65)5.41 (7.31)0.15
Erosion SHS¶1.33 (2.63)1.87 (3.54)0.26
Joint-space narrowing SHS¶3.33 (7.46)3.54 (5.5)0.44